rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a prospective vaccine against tuberculosis created by a team headed by Marcus A. Horwitz at UCLA.
rBCG30 (recombinant Bacillus Calmette-Guérin 30) is a potential vaccine against tuberculosis developed by a team led by Marcus A. Horwitz at UCLA.